Related Experiment Video
Updated: Jun 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
[Treatment of myeloproliferative neoplasms other than chronic leukemia]
1Intractable Diseases Research Center, Tokyo Medical University.
Abstract:
The discovery of JAK2 mutation has greatly facilitated the approach to diagnosis of myeloproliferative neoplasms besides chronic myeloid leukemia. Since major causes of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET) are represented by thrombosis, bleeding, progression to myelofiblosis, and tranfromation to leukemia, risk oriented therapeutic approach is recommended. Established risk factors for cardiovascular events are represented by older age (age over 60) and previous thrombosis. While there are some concerns, the JAK2 mutational status as well as mutant allele burden might be a new surrogate marker for stratified management of PV and ET. Finally, there is a great expectation for novel drugs targeting the constitutively active JAK2/STAT pathway.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers